Graves’ Disease PBMC
Graves' Disease PBMC - Cryopreserved PBMCs in CryoStor CS10 from IRB-consented donors with clinically confirmed Graves' disease, an autoimmune thyroid disorder driven by stimulating TSH receptor autoantibodies. Ideal for autoreactive B cell and T helper studies, ex vivo stimulation, repertoire sequencing, and immunomodulator screening.
| Lot # | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 71781 | Graves' Disease | 50M | Asian/Pacific Islander | 38 | Male | United States |
Methimazole 5mg QD; QVAR 80mcg/2xday; Propranolol 10mg QD
|
133 | $1,208.00 | |
| 71781 | Graves' Disease | 10M | Asian/Pacific Islander | 38 | Male | United States |
Methimazole 5mg QD; QVAR 80mcg/2xday; Propranolol 10mg QD
|
2 | ||
| 70526 | Graves' Disease | 10M | Native American | 63 | Male | United States | 2 | |||
| 69291 | Graves' Disease | 50M | Asian/Pacific Islander | 66 | Male | United States |
No medications
|
116 | $1,208.00 | |
| 69291 | Graves' Disease | 10M | Asian/Pacific Islander | 66 | Male | United States |
No medications
|
1 | ||
| 69382 | Graves' Disease | 10M | Caucasian | 63 | Female | United States |
Levothyroxine, liothyronine. Temazapam Levothyroxine 88 mcg QD Liothyronine 5 mcg QD Hizentra 12gm/60 ml Infusion QD
|
4 | ||
| 69291 | Graves' Disease | 50M | Asian/Pacific Islander | 66 | Male |
No medications
|
2 | $1,208.00 | + Add to Cart | |
| 71781 | Graves' Disease | 50M | Asian/Pacific Islander | 38 | Male |
Methimazole 5mg QD; QVAR 80mcg/2xday; Propranolol 10mg QD
|
1 | $1,208.00 |
Graves’ Disease PBMC for Autoimmune Thyroid Disease Research
Graves’ Disease Human PBMC products are sourced from IRB-consented donors clinically diagnosed with Graves’ disease and processed within 24 hours of collection under standardized SOPs. These cryopreserved peripheral blood mononuclear cells are stored in CryoStor® CS10 and shipped on dry ice. Research Use Only (RUO).
Disease Immunology and Why PBMC
- Graves’ disease is an autoimmune disorder in which autoantibodies against the thyroid-stimulating hormone receptor (TSHR) act as receptor agonists, driving unregulated thyroid hormone production and hyperthyroidism.
- This agonist mechanism distinguishes Graves’ disease from most autoantibody-mediated conditions, where autoantibodies are blocking or destructive rather than stimulating. TSHR antibody status is the defining serological feature.
- Autoantibody production depends on B cells, but requires CD4 T cell help; altered T helper and regulatory T cell balance in circulating lymphocytes is a long-standing focus of research in the disease.
- Thyroid eye disease, or Graves’ orbitopathy, involves orbital fibroblasts that express both TSHR and the insulin-like growth factor 1 receptor; IGF-1R is a validated therapeutic target in that manifestation.
- PBMCs give access to the autoreactive B cell and helper T cell compartments for immunophenotyping, ex vivo antigen stimulation, and repertoire sequencing. Serum and plasma can measure the antibody but cannot interrogate the cells that make it.
- Donor-matched PBMCs also support functional assays for B cell-directed and immunomodulatory therapeutic candidates.
Donor Stratification Available
- TSHR antibody status and titer where documented
- Thyroid function state at collection: untreated hyperthyroid, biochemically euthyroid on therapy, or hypothyroid post-treatment
- Presence and activity of thyroid eye disease
- Treatment status: antithyroid drug therapy, radioiodine, thyroidectomy, biologic therapy, or treatment-naive
- Disease duration and relapse history
- Coexisting autoimmune conditions, plus age, sex, and self-reported race/ethnicity
- Matched healthy controls available
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed Graves’ disease donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified Graves’ disease diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Thyroid function status, antibody status, and treatment history where available
- Additional Graves’ disease-specific data available upon request
Applications
- Immunophenotyping of B cell, T helper, and regulatory T cell compartments
- Autoreactive B cell characterization and antibody repertoire sequencing
- Ex vivo antigen and mitogen stimulation with cytokine release readouts
- Mechanism-of-action studies for B cell-depleting and immunomodulatory candidates
- IGF-1R and TSHR pathway research relevant to thyroid eye disease
- Bulk and single-cell transcriptomic profiling
- Biomarker discovery and validation for relapse risk
- Drug screening and therapeutic development
Other Graves’ Disease Specimen Types
- Graves’ Disease Plasma
- Graves’ Disease Serum
- Graves’ Disease Whole Blood
- Graves’ Disease Leukopak
- Graves’ Disease Bulk Plasma
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Customization
Graves’ Disease PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability, international orders, or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To browse all donor cohorts and current stock, visit our human PBMCs page.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.